Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Another Strong Quarter For AbbVie, But How Long Will Good Times Last?

Jul 30 2016

• By Joseph Haas

Related Content

Sales Down, Discounts Up: Hepatitis C Market Feeling Zepatier Launch

May 13 2016

Merck Defends Its Offensive Strategy For Keytruda

Jul 30 2016

Courts, Not FDA Panel, Likely Bigger Hurdle For Amgen's Humira Biosimilar

Jul 10 2016

AbbVie Banks On “Pipeline In A Molecule” Strategy For Imbruvica

Mar 09 2015

AbbVie Gains Lung Cancer ADC, Solid Tumor Platform With Stemcentrx Buyout

Apr 28 2016

Biosimilar Litigation: Battles Continue Over Launch Notification, Access To FDA Info

Jul 26 2016

Amgen's Humira Biosimilar Gains Nod From Panel Perplexed By Regulatory Pathway

Jul 13 2016

Was Rova-T Worth The High Price To AbbVie?

Jun 07 2016

Related Companies

AbbVie Inc.

Bristol Myers Squibb Company

Merck & Co., Inc.

Amgen, Inc.

Gilead Sciences, Inc.

Additional Topics

Commercial Immune Disorders Gastrointestinal Dermatology Infectious Diseases Cancer BioPharmaceutical

More from Immunological

More from Therapy Areas

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window